Strategic collaborations are an important component of Liquidia’s short- and long-term plans to accelerate PRINT®-enabled therapies into commercial use. Liquidia seeks collaborations with global and regional biopharmaceutical leaders, emerging biotech companies and leading academic institutions. Liquidia and its collaborators come together to create products that solve problems that current therapies are not able to address.
If you are interested in working with us, CLICK HERE.
In June 2012, Liquidia entered a broad, multi-year collaboration with GlaxoSmithKline (GSK), which acquired exclusive rights to research and develop certain inhaled therapies using Liquidia’s PRINT technology. In September 2015, GSK exercised its option to exclusively license the right to research, develop, and commercialize inhaled therapeutics based on Liquidia’s PRINT technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies.
In October 2017, Aerie Pharmaceuticals acquired the rights to use PRINT Technology in ophthalmology and certain other assets from Envisia Therapeutics, a Liquidia spin-out. Aerie is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Liquidia is applying its novel PRINT technology across multiple therapeutic areas.